JS McLellan

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background An immune correlates study of the RV144 vaccine trial demonstrated that elicitation of V1/V2-directed antibodies was inversely associated with infection risk. In addition, a sieve analysis of breakthrough infections identified residue 169 in the V2 loop as a site of immune pressure. Antibodies CH58 and CH59 were isolated from RV144 vaccinees and(More)
Background The somatically related antibodies, PG9 and PG16, neutralize 70-80% of HIV-1 isolates and bind a glycosylated epitope in the V1/V2 domain of HIV-1 gp120. Mutations in V1/V2, and sometimes V3 depending on the HIV-1 strain, affect neutralization and a glycan on Asn160 is required for neutralization. Both antibodies also preferentially bind the(More)
Background Antibody PG9 is a prototypical member of a class of V1/V2-directed antibodies that effectively neutralizes diverse strains of HIV-1. The crystal structure of PG9 bound to scaffolded V1/V2 has provided insight into its mode of recognition. We sought to gain a more complete understanding of the interaction of PG9 with the functional viral spike,(More)
  • 1